Cargando…

Weipiling decoction alleviates N-methyl-N-nitro-N′-nitrosoguanidine-induced gastric precancerous lesions via NF-κB signalling pathway inhibition

AIM OF THE STUDY: We aimed to explore how weipiling (WPL) decoction WPL alleviates gastric precancerous lesions (GPLs) and uncover its anti-inflammatory roles in GPL treatment. MATERIALS AND METHODS: The anti-GPL action mechanisms of WPL were analysed using a network pharmacological method. The WPL...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Penghui, Yang, Hongmei, Zhou, Hengli, Li, Qiuyue, Wei, Sufen, Wang, Qi, Yan, Yan, Liu, Yongqiang, Pan, Huafeng, Li, Siyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463785/
https://www.ncbi.nlm.nih.gov/pubmed/36085156
http://dx.doi.org/10.1186/s13020-022-00663-y
_version_ 1784787462166413312
author Yang, Penghui
Yang, Hongmei
Zhou, Hengli
Li, Qiuyue
Wei, Sufen
Wang, Qi
Yan, Yan
Liu, Yongqiang
Pan, Huafeng
Li, Siyi
author_facet Yang, Penghui
Yang, Hongmei
Zhou, Hengli
Li, Qiuyue
Wei, Sufen
Wang, Qi
Yan, Yan
Liu, Yongqiang
Pan, Huafeng
Li, Siyi
author_sort Yang, Penghui
collection PubMed
description AIM OF THE STUDY: We aimed to explore how weipiling (WPL) decoction WPL alleviates gastric precancerous lesions (GPLs) and uncover its anti-inflammatory roles in GPL treatment. MATERIALS AND METHODS: The anti-GPL action mechanisms of WPL were analysed using a network pharmacological method. The WPL extract was prepared in a traditional way and evaluated for its major components using high-performance liquid chromatography with tandem mass spectrometry (HPLC–MS/MS). BALB/c mice were exposed to N-methyl-N-nitro-N-nitrosoguanidine (MNNG) (150 μg/mL) for 6 weeks to induce GPLs. GPL mice were administered WPL (3.75 g/kg/day and 15 g/kg/day) for an additional 8 weeks. Haematoxylin and eosin (H&E) staining was used to investigate histological alterations in gastric tissues. Expression of the T helper 1 (Th1) cell markers CD4(+) and interferon-gamma (INF-γ) were tested using immunohistochemistry (IHC). Inflammatory protein and mRNA levels in the nuclear factor kappa B (NF-κB) pathway were detected using western blotting and a quantitative reverse transcription polymerase chain reaction (RT-qPCR), respectively. RESULTS: We identified and selected 110 active compounds and 146 targets from public databases and references. Four representative components of WPL were established and quantified by HPLC–MS/MS analysis. WPL attenuated MNNG-induced GPLs, including epithelial shedding, cavity fusion, basement membranes with asymmetrical thickness, intestinal metaplasia, dysplasia, pro-inflammatory Th1-cell infiltration, and INF-γ production, indicating that WPL prevents inflammation in the gastric mucosa. Furthermore, WPL reversed MNNG-induced activation of the IκB/NF-κB signalling pathway and subsequently attenuated the upregulation of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase (NOX)) family members NOX2 and NOX4. CONCLUSION: WPL attenuated GPLs by controlling the generation of pro-inflammatory elements and inhibiting the NF-κB signalling pathway in vivo.
format Online
Article
Text
id pubmed-9463785
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94637852022-09-11 Weipiling decoction alleviates N-methyl-N-nitro-N′-nitrosoguanidine-induced gastric precancerous lesions via NF-κB signalling pathway inhibition Yang, Penghui Yang, Hongmei Zhou, Hengli Li, Qiuyue Wei, Sufen Wang, Qi Yan, Yan Liu, Yongqiang Pan, Huafeng Li, Siyi Chin Med Research AIM OF THE STUDY: We aimed to explore how weipiling (WPL) decoction WPL alleviates gastric precancerous lesions (GPLs) and uncover its anti-inflammatory roles in GPL treatment. MATERIALS AND METHODS: The anti-GPL action mechanisms of WPL were analysed using a network pharmacological method. The WPL extract was prepared in a traditional way and evaluated for its major components using high-performance liquid chromatography with tandem mass spectrometry (HPLC–MS/MS). BALB/c mice were exposed to N-methyl-N-nitro-N-nitrosoguanidine (MNNG) (150 μg/mL) for 6 weeks to induce GPLs. GPL mice were administered WPL (3.75 g/kg/day and 15 g/kg/day) for an additional 8 weeks. Haematoxylin and eosin (H&E) staining was used to investigate histological alterations in gastric tissues. Expression of the T helper 1 (Th1) cell markers CD4(+) and interferon-gamma (INF-γ) were tested using immunohistochemistry (IHC). Inflammatory protein and mRNA levels in the nuclear factor kappa B (NF-κB) pathway were detected using western blotting and a quantitative reverse transcription polymerase chain reaction (RT-qPCR), respectively. RESULTS: We identified and selected 110 active compounds and 146 targets from public databases and references. Four representative components of WPL were established and quantified by HPLC–MS/MS analysis. WPL attenuated MNNG-induced GPLs, including epithelial shedding, cavity fusion, basement membranes with asymmetrical thickness, intestinal metaplasia, dysplasia, pro-inflammatory Th1-cell infiltration, and INF-γ production, indicating that WPL prevents inflammation in the gastric mucosa. Furthermore, WPL reversed MNNG-induced activation of the IκB/NF-κB signalling pathway and subsequently attenuated the upregulation of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase (NOX)) family members NOX2 and NOX4. CONCLUSION: WPL attenuated GPLs by controlling the generation of pro-inflammatory elements and inhibiting the NF-κB signalling pathway in vivo. BioMed Central 2022-09-09 /pmc/articles/PMC9463785/ /pubmed/36085156 http://dx.doi.org/10.1186/s13020-022-00663-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yang, Penghui
Yang, Hongmei
Zhou, Hengli
Li, Qiuyue
Wei, Sufen
Wang, Qi
Yan, Yan
Liu, Yongqiang
Pan, Huafeng
Li, Siyi
Weipiling decoction alleviates N-methyl-N-nitro-N′-nitrosoguanidine-induced gastric precancerous lesions via NF-κB signalling pathway inhibition
title Weipiling decoction alleviates N-methyl-N-nitro-N′-nitrosoguanidine-induced gastric precancerous lesions via NF-κB signalling pathway inhibition
title_full Weipiling decoction alleviates N-methyl-N-nitro-N′-nitrosoguanidine-induced gastric precancerous lesions via NF-κB signalling pathway inhibition
title_fullStr Weipiling decoction alleviates N-methyl-N-nitro-N′-nitrosoguanidine-induced gastric precancerous lesions via NF-κB signalling pathway inhibition
title_full_unstemmed Weipiling decoction alleviates N-methyl-N-nitro-N′-nitrosoguanidine-induced gastric precancerous lesions via NF-κB signalling pathway inhibition
title_short Weipiling decoction alleviates N-methyl-N-nitro-N′-nitrosoguanidine-induced gastric precancerous lesions via NF-κB signalling pathway inhibition
title_sort weipiling decoction alleviates n-methyl-n-nitro-n′-nitrosoguanidine-induced gastric precancerous lesions via nf-κb signalling pathway inhibition
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463785/
https://www.ncbi.nlm.nih.gov/pubmed/36085156
http://dx.doi.org/10.1186/s13020-022-00663-y
work_keys_str_mv AT yangpenghui weipilingdecoctionalleviatesnmethylnnitronnitrosoguanidineinducedgastricprecancerouslesionsvianfkbsignallingpathwayinhibition
AT yanghongmei weipilingdecoctionalleviatesnmethylnnitronnitrosoguanidineinducedgastricprecancerouslesionsvianfkbsignallingpathwayinhibition
AT zhouhengli weipilingdecoctionalleviatesnmethylnnitronnitrosoguanidineinducedgastricprecancerouslesionsvianfkbsignallingpathwayinhibition
AT liqiuyue weipilingdecoctionalleviatesnmethylnnitronnitrosoguanidineinducedgastricprecancerouslesionsvianfkbsignallingpathwayinhibition
AT weisufen weipilingdecoctionalleviatesnmethylnnitronnitrosoguanidineinducedgastricprecancerouslesionsvianfkbsignallingpathwayinhibition
AT wangqi weipilingdecoctionalleviatesnmethylnnitronnitrosoguanidineinducedgastricprecancerouslesionsvianfkbsignallingpathwayinhibition
AT yanyan weipilingdecoctionalleviatesnmethylnnitronnitrosoguanidineinducedgastricprecancerouslesionsvianfkbsignallingpathwayinhibition
AT liuyongqiang weipilingdecoctionalleviatesnmethylnnitronnitrosoguanidineinducedgastricprecancerouslesionsvianfkbsignallingpathwayinhibition
AT panhuafeng weipilingdecoctionalleviatesnmethylnnitronnitrosoguanidineinducedgastricprecancerouslesionsvianfkbsignallingpathwayinhibition
AT lisiyi weipilingdecoctionalleviatesnmethylnnitronnitrosoguanidineinducedgastricprecancerouslesionsvianfkbsignallingpathwayinhibition